MX2020003619A - Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa. - Google Patents

Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa.

Info

Publication number
MX2020003619A
MX2020003619A MX2020003619A MX2020003619A MX2020003619A MX 2020003619 A MX2020003619 A MX 2020003619A MX 2020003619 A MX2020003619 A MX 2020003619A MX 2020003619 A MX2020003619 A MX 2020003619A MX 2020003619 A MX2020003619 A MX 2020003619A
Authority
MX
Mexico
Prior art keywords
administration
treatment
antibodies
patients
dosage
Prior art date
Application number
MX2020003619A
Other languages
English (en)
Inventor
Guiseppe REMUZZI
Piero Ruggenenti
Xiang Gao
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2020003619A publication Critical patent/MX2020003619A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos para el tratamiento clínico de la glomerulonefritis membranoproliferativa (MPGN), por medio de la administración de un anticuerpo anti-C5, o de un fragmento de enlace al antígeno del mismo.
MX2020003619A 2017-10-04 2018-10-02 Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa. MX2020003619A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568060P 2017-10-04 2017-10-04
US201862652615P 2018-04-04 2018-04-04
PCT/US2018/053976 WO2019070714A1 (en) 2017-10-04 2018-10-02 ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT

Publications (1)

Publication Number Publication Date
MX2020003619A true MX2020003619A (es) 2020-10-28

Family

ID=64051671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003619A MX2020003619A (es) 2017-10-04 2018-10-02 Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa.

Country Status (11)

Country Link
US (2) US20200262897A1 (es)
EP (1) EP3692064A1 (es)
JP (2) JP2020536097A (es)
KR (1) KR20200059279A (es)
CN (1) CN111278857A (es)
AU (1) AU2018345625A1 (es)
BR (1) BR112020006692A2 (es)
CA (1) CA3078362A1 (es)
CO (1) CO2020004831A2 (es)
MX (1) MX2020003619A (es)
WO (1) WO2019070714A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
JP2021525860A (ja) * 2018-05-25 2021-09-27 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体代替経路関連腎症バイオマーカー
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
CA3114039A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CN109045296A (zh) * 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2016209956A1 (en) * 2015-06-26 2016-12-29 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
CN115925922A (zh) * 2016-06-17 2023-04-07 中外制药株式会社 抗-c5抗体及使用方法

Also Published As

Publication number Publication date
US20240025975A1 (en) 2024-01-25
CO2020004831A2 (es) 2020-05-29
BR112020006692A2 (pt) 2020-10-06
JP2020536097A (ja) 2020-12-10
CA3078362A1 (en) 2019-04-11
JP2023101717A (ja) 2023-07-21
US20200262897A1 (en) 2020-08-20
CN111278857A (zh) 2020-06-12
AU2018345625A1 (en) 2020-04-16
WO2019070714A1 (en) 2019-04-11
EP3692064A1 (en) 2020-08-12
KR20200059279A (ko) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2020003619A (es) Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa.
MX2020004284A (es) Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua).
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
UY36194A (es) Anticuerpos anti-tau humanizados
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
MX2016013857A (es) Anticuerpos anti-rnf43 novedosos y metodos de uso.
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
CU24556B1 (es) Anticuerpos anti-basigin humanizados
MX2017015311A (es) Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
CO2019002550A2 (es) Anticuerpos anti-gm-csf y usos de los mismos
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
BR112017003252A2 (pt) terapia com anticorpos contra hiv como substituto de tratamento
CO2022009246A2 (es) Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis óptica
EA201892244A1 (ru) МОНОВАЛЕНТНЫЙ ИНГИБИТОР ВЗАИМОДЕЙСТВИЯ huTNFR1
CL2014003373A1 (es) Anticuerpos monoclonales especificos para el antígeno m del virus metapneumovirus humano (hmpv), producidos y secretados por hibridomas celulares , útiles para la deteccion y el diagnostico de la infeccion causada por hmpv.